Study: Pfizer vaccine is 88% effective against the delta variant
A new study shows that two doses of the Pfizer COVID-19 vaccine are 88% effective against the delta variant.
the study, published in the New England Journal of Medicine on Wednesday from researchers at Public Health England, reassures about the effectiveness of vaccines against the delta variant.
The 88 percent efficacy against the delta variant was slightly lower than the 93.7 percent efficacy against the alpha variant, which was first identified in the UK.
The findings bolster previous data from Public Health England in May, which found an efficacy of 88% against Delta.
They contrast with an Israeli study earlier this month that raised some concern when it found that the Pfizer vaccine was only 64 percent effective against the delta variant, but that study’s methods raised skepticism from some experts.
The study published on Wednesday also examined the AstraZeneca vaccine, which is used in the UK but not in the US.
This vaccine was 67% effective against the delta variant, compared to 74.5% against the alpha variant.
Both vaccines were much less effective after just one dose, about 30 percent, leading officials to urge people to get two doses of the vaccine.
The overwhelming message from US health experts and officials is to get vaccinated, given that vaccines have been found to provide protection even against the delta variant, now prevalent in the US and fueling outbreaks among the unvaccinated due to its transmissibility.
The 88 percent efficacy of the Pfizer vaccine against Delta is also against the appearance of any symptoms. Efficacy against hospitalization and death was found to be higher, although not measured in this study.
“Vaccines work, even against variants,” chirp Angela Rasmussen, a virologist at the University of Saskatchewan, responds to the new study. “Get vaccinated if you haven’t already.”